HC Wainwright Issues Negative Forecast for TARA Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Analysts at HC Wainwright dropped their Q3 2026 earnings per share estimates for Protara Therapeutics in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.36) for the quarter, down from their prior estimate of ($0.31). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($1.44) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.38) EPS, FY2027 earnings at ($1.50) EPS, FY2028 earnings at ($0.43) EPS, FY2029 earnings at $0.56 EPS and FY2030 earnings at $1.09 EPS.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.03).

A number of other analysts also recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. JPMorgan Chase & Co. dropped their target price on shares of Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, May 14th. UBS Group reaffirmed a “buy” rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. Finally, Oppenheimer boosted their target price on shares of Protara Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, May 20th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $26.25.

Protara Therapeutics Stock Performance

Shares of TARA opened at $3.94 on Friday. Protara Therapeutics has a one year low of $2.97 and a one year high of $7.82. The stock has a market cap of $232.85 million, a P/E ratio of -2.92 and a beta of 1.50. The stock has a 50-day moving average of $4.03 and a two-hundred day moving average of $5.03.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. AIGH Capital Management LLC purchased a new position in shares of Protara Therapeutics during the 1st quarter worth $8,454,000. ADAR1 Capital Management LLC increased its holdings in Protara Therapeutics by 3,127.4% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,136,799 shares of the company’s stock valued at $6,059,000 after buying an additional 1,101,576 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Protara Therapeutics during the 4th quarter valued at approximately $5,562,000. Janus Henderson Group PLC boosted its stake in Protara Therapeutics by 21.5% in the fourth quarter. Janus Henderson Group PLC now owns 5,141,616 shares of the company’s stock valued at $27,379,000 after acquiring an additional 910,285 shares during the period. Finally, Integral Health Asset Management LLC boosted its stake in Protara Therapeutics by 60.7% during the 4th quarter. Integral Health Asset Management LLC now owns 2,250,000 shares of the company’s stock valued at $11,992,000 after purchasing an additional 850,000 shares during the period. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.